{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:46:29Z","timestamp":1790736389729,"version":"4.1.0"},"reference-count":124,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,7,27]],"date-time":"2020-07-27T00:00:00Z","timestamp":1595808000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,27]],"date-time":"2020-07-27T00:00:00Z","timestamp":1595808000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medical writing support was funded by Amgen (Europe) GmbH."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2020,9,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The emergence of human intratumoural immunotherapy (HIT-IT) is a major step forward in the management of unresectable melanoma. The direct injection of treatments into melanoma lesions can cause cell lysis and induce a local immune response, and might be associated with a systemic immune response. Directly injecting immunotherapies into tumours achieves a high local concentration of immunostimulatory agent while minimising systemic exposure and, as such, HIT-IT agents are associated with lower toxicity than systemic immune checkpoint inhibitors (CPIs), enabling their potential use in combination with other therapies. Consequently, multiple HIT-IT agents, including oncolytic viruses, pattern-recognition receptor agonists, injected CPIs, cytokines and immune glycolipids, are under investigation. This review considers the current clinical development status of HIT-IT agents as monotherapy and in combination with systemic CPIs, and the practical aspects of administering and assessing the response to these agents. The future of HIT-IT probably lies in its use in combination with systemic CPIs; data from Phase 2 trials indicate a synergy between HIT-IT and CPIs. Data also suggest that the addition of HIT-IT to a CPI might generate responses in CPI-refractory tumours, thereby overcoming resistance and addressing a current unmet need in unresectable and metastatic melanoma for treatment options following progression after CPI treatment.<\/jats:p>","DOI":"10.1038\/s41416-020-0994-4","type":"journal-article","created":{"date-parts":[[2020,7,26]],"date-time":"2020-07-26T23:02:46Z","timestamp":1595804566000},"page":"885-897","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Intratumoural immunotherapies for unresectable and metastatic melanoma: current status and future perspectives"],"prefix":"10.1038","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0167-1685","authenticated-orcid":false,"given":"Mark R.","family":"Middleton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Hoeller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Michielin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Robert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Caramella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina","family":"\u00d6hrling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Hauschild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,27]]},"reference":[{"key":"994_CR1","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1046\/j.1365-2133.2002.04867.x","volume":"147","author":"F Meier","year":"2002","unstructured":"Meier, F., Will, S., Ellwanger, U., Schlagenhauff, B., Schittek, B., Rassner, G. et al. Metastatic pathways and time courses in the orderly progression of cutaneous melanoma. Br. J. Dermatol. 147, 62\u201370 (2002).","journal-title":"Br. J. Dermatol."},{"key":"994_CR2","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00262-016-1944-0","volume":"66","author":"B Weide","year":"2017","unstructured":"Weide, B., Martens, A., Wistuba-Hamprecht, K., Zelba, H., Maier, L., Lipp, H. P. et al. Combined treatment with ipilimumab and intratumoral interleukin-2 in pretreated patients with stage IV melanoma-safety and efficacy in a phase II study. Cancer Immunol. Immunother. 66, 441\u2013449 (2017).","journal-title":"Cancer Immunol. Immunother."},{"key":"994_CR3","doi-asserted-by":"publisher","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","volume":"27","author":"CM Balch","year":"2009","unstructured":"Balch, C. M., Gershenwald, J. E., Soong, S.-J., Thompson, J. F., Atkins, M. B., Byrd, D. R. et al. Final version of 2009 AJCC melanoma staging and classification. J. Clin. Oncol. 27, 6199\u20136206 (2009).","journal-title":"J. Clin. Oncol."},{"key":"994_CR4","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.suc.2014.07.004","volume":"94","author":"AM Abbott","year":"2014","unstructured":"Abbott, A. M. & Zager, J. S. Locoregional therapies in melanoma. Surg. Clin. North Am. 94, 1003\u20131015 (2014).","journal-title":"Surg. Clin. North Am."},{"key":"994_CR5","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s00262-016-1952-0","volume":"66","author":"B Weide","year":"2017","unstructured":"Weide, B., Neri, D. & Elia, G. Intralesional treatment of metastatic melanoma: a review of therapeutic options. Cancer Immunol. Immunother. 66, 647\u2013656 (2017).","journal-title":"Cancer Immunol. Immunother."},{"key":"994_CR6","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","volume":"377","author":"JD Wolchok","year":"2017","unstructured":"Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L. et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 377, 1345\u20131356 (2017).","journal-title":"N. Engl. J. Med."},{"key":"994_CR7","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1200\/JCO.2014.56.6018","volume":"33","author":"M Maio","year":"2015","unstructured":"Maio, M., Grob, J. J., Aamdal, S., Bondarenko, I., Robert, C., Thomas, L. et al. Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J. Clin. Oncol. 33, 1191\u20131196 (2015).","journal-title":"J. Clin. Oncol."},{"key":"994_CR8","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1093\/annonc\/mdz011","volume":"30","author":"O Hamid","year":"2019","unstructured":"Hamid, O., Hersey, P., Wolchok, J. D., Dronca, R., Joseph, R., Weber, J. S. et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann. Oncol. 30, 528\u2013588 (2019).","journal-title":"Ann. Oncol."},{"key":"994_CR9","first-page":"68","volume":"22","author":"J Mackiewicz","year":"2018","unstructured":"Mackiewicz, J. & Mackiewicz, A. BRAF and MEK inhibitors in the era of immunotherapy in melanoma patients. Contemp. Oncol. (Pozn., Pol.) 22, 68\u201372 (2018).","journal-title":"Contemp. Oncol. (Pozn., Pol.)"},{"key":"994_CR10","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma, P., Hu-Lieskovan, S., Wargo, J. A. & Ribas, A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168, 707\u2013723 (2017).","journal-title":"Cell"},{"key":"994_CR11","unstructured":"Bristol-Myers Squibb. Yervoy (ipilimumab): summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/yervoy-epar-product-information_en.pdf (2019)."},{"key":"994_CR12","unstructured":"Merck. KEYTRUDA (pembrolizumab): summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/keytruda-epar-product-information_en.pdf (2019)."},{"key":"994_CR13","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L. et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372, 2521\u20132532 (2015).","journal-title":"N. Engl. J. Med."},{"key":"994_CR14","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S1470-2045(14)70012-9","volume":"15","author":"GA McArthur","year":"2014","unstructured":"McArthur, G. A., Chapman, P. B., Robert, C., Larkin, J., Haanen, J. B., Dummer, R. et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 15, 323\u2013332 (2014).","journal-title":"Lancet Oncol."},{"key":"994_CR15","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","volume":"371","author":"J Larkin","year":"2014","unstructured":"Larkin, J., Ascierto, P. A., Dr\u00e9no, B., Atkinson, V., Liszkay, G., Maio, M. et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N. Engl. J. Med. 371, 1867\u20131876 (2014).","journal-title":"N. Engl. J. Med."},{"key":"994_CR16","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L. et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372, 320\u2013330 (2015).","journal-title":"N. Engl. J. Med."},{"key":"994_CR17","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","volume":"380","author":"A Hauschild","year":"2012","unstructured":"Hauschild, A., Grob, J. J., Demidov, L. V., Jouary, T., Gutzmer, R., Millward, M. et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380, 358\u2013365 (2012).","journal-title":"Lancet"},{"key":"994_CR18","doi-asserted-by":"publisher","first-page":"4169","DOI":"10.1245\/s10434-016-5286-0","volume":"23","author":"RH Andtbacka","year":"2016","unstructured":"Andtbacka, R. H., Ross, M., Puzanov, I., Milhem, M., Collichio, F., Delman, K. A. et al. Patterns of clinical response with talimogene laherparepvec (T-VEC) in patients with melanoma treated in the OPTiM phase III clinical trial. Ann. Surg. Oncol. 23, 4169\u20134177 (2016).","journal-title":"Ann. Surg. Oncol."},{"key":"994_CR19","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1245\/s10434-014-4169-5","volume":"22","author":"JF Thompson","year":"2015","unstructured":"Thompson, J. F., Agarwala, S. S., Smithers, B. M., Ross, M. I., Scoggins, C. R., Coventry, B. J. et al. Phase 2 study of intralesional PV-10 in refractory metastatic melanoma. Ann. Surg. Oncol. 22, 2135\u20132142 (2015).","journal-title":"Ann. Surg. Oncol."},{"key":"994_CR20","first-page":"436","volume":"30","author":"SS Agarwala","year":"2016","unstructured":"Agarwala, S. S. The role of intralesional therapies in melanoma. Oncol. (Williston Park) 30, 436\u2013441 (2016).","journal-title":"Oncol. (Williston Park)"},{"key":"994_CR21","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1093\/annonc\/mdy423","volume":"29","author":"A Marabelle","year":"2018","unstructured":"Marabelle, A., Andtbacka, R., Harrington, K., Melero, I., Leidner, R., de Baere, T. et al. Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT). Ann. Oncol. 29, 2163\u20132174 (2018).","journal-title":"Ann. Oncol."},{"key":"994_CR22","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","volume":"33","author":"RH Andtbacka","year":"2015","unstructured":"Andtbacka, R. H., Kaufman, H. L., Collichio, F., Amatruda, T., Senzer, N., Chesney, J. et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J. Clin. Oncol. 33, 2780\u20132788 (2015).","journal-title":"J. Clin. Oncol."},{"key":"994_CR23","doi-asserted-by":"publisher","first-page":"3960","DOI":"10.1245\/s10434-018-6803-0","volume":"25","author":"MC Perez","year":"2018","unstructured":"Perez, M. C., Miura, J. T., Naqvi, S. M. H., Kim, Y., Holstein, A., Lee, D. et al. Talimogene laherparepvec (TVEC) for the treatment of advanced melanoma: a single-institution experience. Ann. Surg. Oncol. 25, 3960\u20133965 (2018).","journal-title":"Ann. Surg. Oncol."},{"key":"994_CR24","doi-asserted-by":"publisher","first-page":"e68561","DOI":"10.1371\/journal.pone.0068561","volume":"8","author":"P Toomey","year":"2013","unstructured":"Toomey, P., Kodumudi, K., Weber, A., Kuhn, L., Moore, E., Sarnaik, A. A. et al. Intralesional injection of rose bengal induces a systemic tumor-specific immune response in murine models of melanoma and breast cancer. PLoS ONE 8, e68561 (2013).","journal-title":"PLoS ONE"},{"key":"994_CR25","first-page":"39","volume":"31","author":"J Malvehy","year":"2017","unstructured":"Malvehy, J., Samoylenko, I., Schadendorf, D., Gutzmer, R., Grob, J. J., Sacco, J. et al. Relationship between talimogene laherparepvec and intratumoral CD8+ density in patients with unresectable stage IIIB-IVM1c melanoma: Interim efficacy, safety and biomarker results of a Phase 2 study. J. Eur. Acad. Dermatol. 31, 39\u201340 (2017).","journal-title":"J. Eur. Acad. Dermatol."},{"key":"994_CR26","first-page":"1193","volume":"53","author":"D Wang","year":"2018","unstructured":"Wang, D., Jiang, W., Zhu, F., Mao, X. & Agrawal, S. Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy. Int. J. Oncol. 53, 1193\u20131203 (2018).","journal-title":"Int. J. Oncol."},{"key":"994_CR27","doi-asserted-by":"publisher","first-page":"64390","DOI":"10.18632\/oncotarget.10453","volume":"7","author":"A Ray","year":"2016","unstructured":"Ray, A., Williams, M. A., Meek, S. M., Bowen, R. C., Grossmann, K. F., Andtbacka, R. H. I. et al. A phase I study of intratumoral ipilimumab and interleukin-2 in patients with advanced melanoma. Oncotarget 7, 64390\u201364399 (2016).","journal-title":"Oncotarget"},{"key":"994_CR28","doi-asserted-by":"publisher","first-page":"xii33","DOI":"10.1093\/annonc\/mdx683","volume":"28","author":"A Marabelle","year":"2017","unstructured":"Marabelle, A., Tselikas, L., de Baere, T. & Houot, R. Intratumoral immunotherapy: using the tumor as the remedy. Ann. Oncol. 28, xii33\u2013xii43 (2017).","journal-title":"Ann. Oncol."},{"key":"994_CR29","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s00262-015-1704-6","volume":"64","author":"R Danielli","year":"2015","unstructured":"Danielli, R., Patuzzo, R., Di Giacomo, A. M., Gallino, G., Maurichi, A., Di Florio, A. et al. Intralesional administration of L19-IL2\/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study. Cancer Immunol. Immunother. 64, 999\u20131009 (2015).","journal-title":"Cancer Immunol. Immunother."},{"key":"994_CR30","doi-asserted-by":"publisher","first-page":"4139","DOI":"10.1002\/cncr.25156","volume":"116","author":"B Weide","year":"2010","unstructured":"Weide, B., Derhovanessian, E., Pflugfelder, A., Eigentler, T. K., Radny, P., Zelba, H. et al. High response rate after intratumoral treatment with interleukin-2: results from a phase 2 study in 51 patients with metastasized melanoma. Cancer 116, 4139\u20134146 (2010).","journal-title":"Cancer"},{"issue":"Suppl 8","key":"994_CR31","doi-asserted-by":"publisher","first-page":"viii442","DOI":"10.1093\/annonc\/mdy289.001","volume":"29","author":"A Diab","year":"2018","unstructured":"Diab, A., Haymaker, C., Bernatchez, C., Andtbacka, R., Shaheen, M., Johnson, D. H. et al. Intratumoral (IT) Injection of the TLR9 agonist tilsotolimod (IMO-2125) in combination with ipilimumab (ipi) triggers durable responses in PD-1 inhibitor refractory metastatic melanoma (rMM): Results from a multicenter, phase I\/II study. Ann. Oncol. 29(Suppl 8), viii442 (2018).","journal-title":"Ann. Oncol."},{"issue":"Suppl 1","key":"994_CR32","doi-asserted-by":"crossref","first-page":"CT144","DOI":"10.1158\/1538-7445.AM2018-CT144","volume":"78","author":"M Milhem","year":"2018","unstructured":"Milhem, M., Gonzales, R., Medina, T., Kirkwood, J. M., Buchbinder, E., Mehmi, I. et al. Intratumoral toll-like receptor 9 (TLR9) agonist, CMP-001, in combination with pembrolizumab can reverse resistance to PD-1 inhibition in a phase Ib trial in subjects with advanced melanoma. Cancer Res. 78(Suppl 1), CT144 (2018).","journal-title":"Cancer Res."},{"issue":"Suppl 8","key":"994_CR33","doi-asserted-by":"publisher","first-page":"viii451","DOI":"10.1093\/annonc\/mdy289.021","volume":"29","author":"A Ribas","year":"2018","unstructured":"Ribas, A., Mehmi, I., Medina, D., Lao, C., Kummar, S., Amin, A. et al. Phase Ib\/II study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who had progressive disease on or after prior anti-PD-1 therapy. Ann. Oncol. 29(Suppl 8), viii451\u2013viii452 (2018).","journal-title":"Ann. Oncol."},{"issue":"Suppl 6","key":"994_CR34","doi-asserted-by":"publisher","first-page":"vi360","DOI":"10.1093\/annonc\/mdw378.06","volume":"27","author":"B Curti","year":"2016","unstructured":"Curti, B., Richards, J., Faries, M. B., Andtbacka, R. H., Grose, M., Karpathy, R. et al. The MITCI (phase 1b) study: novel immunotherapy combination of coxsackievirus A21 and ipilimumab in patients with advanced melanoma. Ann. Oncol. 27(Suppl 6), vi360 (2016).","journal-title":"Ann. Oncol."},{"key":"994_CR35","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s00262-017-1967-1","volume":"66","author":"R Dummer","year":"2017","unstructured":"Dummer, R., Hoeller, C., Gruter, I. P. & Michielin, O. Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors. Cancer Immunol. Immunother. 66, 683\u2013695 (2017).","journal-title":"Cancer Immunol. Immunother."},{"issue":"Suppl 13","key":"994_CR36","doi-asserted-by":"crossref","first-page":"CT026","DOI":"10.1158\/1538-7445.AM2017-CT026","volume":"77","author":"AW Silk","year":"2017","unstructured":"Silk, A. W., Kaufman, H. L., Gabrail, N., Faries, M. B., Mehnert, J., Bryan, J. et al. Phase Ib study of intratumoral oncolytic Coxsackievirus A21 (CVA21) and systemic pembrolizumab in subjects with advanced melanoma: interim results of the CAPRA clinical trial. Cancer Res. 77(Suppl 13), CT026 (2017).","journal-title":"Cancer Res."},{"key":"994_CR37","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","volume":"170","author":"A Ribas","year":"2017","unstructured":"Ribas, A., Dummer, R., Puzanov, I., VanderWalde, A., Andtbacka, R. H., Michielin, O. et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell 170, 1109\u20131119 (2017).","journal-title":"Cell"},{"key":"994_CR38","doi-asserted-by":"publisher","first-page":"6190","DOI":"10.1158\/1078-0432.CCR-17-0681","volume":"23","author":"AK Moesta","year":"2017","unstructured":"Moesta, A. K., Cooke, K., Piasecki, J., Mitchell, P., Rottman, J. B., Fitzgerald, K. et al. Local delivery of OncoVEXmGM-CSF generates systemic antitumor immune responses enhanced by cytotoxic T-lymphocyte-associated protein blockade. Clin. Cancer Res. 23, 6190\u20136202 (2017).","journal-title":"Clin. Cancer Res."},{"key":"994_CR39","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1200\/JCO.2017.73.7379","volume":"36","author":"J Chesney","year":"2018","unstructured":"Chesney, J., Puzanov, I., Collichio, F., Singh, P., Milhem, M. M., Glaspy, J. et al. Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma. J. Clin. Oncol. 36, 1658\u20131667 (2018).","journal-title":"J. Clin. Oncol."},{"key":"994_CR40","unstructured":"Amgen. Imlygic (T-VEC): prescribing information. https:\/\/www.fda.gov\/media\/94129\/download (2015)."},{"key":"994_CR41","unstructured":"Amgen. Imlygic (T-VEC): summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/imlygic-epar-product-information_en.pdf (2019)."},{"key":"994_CR42","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1093\/annonc\/mdz411","volume":"30","author":"O Michielin","year":"2019","unstructured":"Michielin, O., van Akkooi, A. C. J., Ascierto, P. A., Dummer, R. & Keilholz, U. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 30, 1884\u20131901 (2019).","journal-title":"Ann. Oncol."},{"key":"994_CR43","doi-asserted-by":"crossref","unstructured":"Garbe, C., Peris, K., Hauschild, A., Saiag, P., Middleton, M., Bastholt, L. et al. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline\u2014update 2016. Eur. J. Cancer 63, 201\u2013217 (2016).","DOI":"10.1016\/j.ejca.2016.05.005"},{"key":"994_CR44","unstructured":"National Comprehensive Cancer Network. NCCN Guidelines version 2. 2019 Melanoma. 2019. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cutaneous_melanoma.pdf"},{"key":"994_CR45","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/jso.23556","volume":"109","author":"CF Temple-Oberle","year":"2014","unstructured":"Temple-Oberle, C. F., Byers, B. A., Hurdle, V., Fyfe, A. & McKinnon, J. G. Intra-lesional interleukin-2 therapy for in transit melanoma. J. Surg. Oncol. 109, 327\u2013331 (2014).","journal-title":"J. Surg. Oncol."},{"key":"994_CR46","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1002\/jso.23702","volume":"110","author":"BA Byers","year":"2014","unstructured":"Byers, B. A., Temple-Oberle, C. F., Hurdle, V. & McKinnon, J. G. Treatment of in-transit melanoma with intra-lesional interleukin-2: a systematic review. J. Surg. Oncol. 110, 770\u2013775 (2014).","journal-title":"J. Surg. Oncol."},{"key":"994_CR47","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s00262-010-0957-3","volume":"60","author":"B Weide","year":"2011","unstructured":"Weide, B., Eigentler, T. K., Pflugfelder, A., Leiter, U., Meier, F., Bauer, J. et al. Survival after intratumoral interleukin-2 treatment of 72 melanoma patients and response upon the first chemotherapy during follow-up. Cancer Immunol. Immunother. 60, 487\u2013493 (2011).","journal-title":"Cancer Immunol. Immunother."},{"key":"994_CR48","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/2051-1426-2-11","volume":"2","author":"HL Kaufman","year":"2014","unstructured":"Kaufman, H. L., Ruby, C. E., Hughes, T. & Slingluff, C. L. Jr. Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma. J. Immunother. Cancer 2, 11 (2014).","journal-title":"J. Immunother. Cancer"},{"key":"994_CR49","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/sj.gt.3301885","volume":"10","author":"BL Liu","year":"2003","unstructured":"Liu, B. L., Robinson, M., Han, Z. Q., Branston, R. H., English, C., Reay, P. et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther. 10, 292\u2013303 (2003).","journal-title":"Gene Ther."},{"issue":"Suppl 8","key":"994_CR50","doi-asserted-by":"publisher","first-page":"viii443","DOI":"10.1093\/annonc\/mdy289.002","volume":"29","author":"H Gogas","year":"2018","unstructured":"Gogas, H., Samoylenko, I., Schadendorf, D., Gutzmer, R., Grob, J. J., Sacco, J. et al. Talimogene laherparepvec treatment increases intratumoural effector T-cell and natural killer (NK) cell density in noninjected tumours in patients with stage IIIB\u2013IVM1c melanoma: evidence for systemic effects in a phase 2, single-arm study. Ann. Oncol. 29(Suppl 8), viii443 (2018).","journal-title":"Ann. Oncol."},{"key":"994_CR51","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1038\/sj.bjc.6605438","volume":"101","author":"G Al\u00ec","year":"2009","unstructured":"Al\u00ec, G., Boldrini, L., Lucchi, M., Picchi, A., Dell\u2019Omodarme, M., Prati, M. C. et al. Treatment with interleukin-2 in malignant pleural mesothelioma: immunological and angiogenetic assessment and prognostic impact. Br. J. Cancer 101, 1869\u20131875 (2009).","journal-title":"Br. J. Cancer"},{"key":"994_CR52","unstructured":"Novartis. Proleukin (aldesleukin): prescribing information. https:\/\/www.proleukin.com\/downloads\/proleukin-pi.pdf (2015)."},{"key":"994_CR53","unstructured":"Novartis. Proleukin (adesleukin): summary of product characteristics. https:\/\/www.medicines.org.uk\/emc\/product\/291\/smpc (2019)."},{"key":"994_CR54","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/s41568-018-0009-4","volume":"18","author":"K Twumasi-Boateng","year":"2018","unstructured":"Twumasi-Boateng, K., Pettigrew, J. L., Kwok, Y. Y. E., Bell, J. C. & Nelson, B. H. Oncolytic viruses as engineering platforms for combination immunotherapy. Nat. Rev. Cancer 18, 419\u2013432 (2018).","journal-title":"Nat. Rev. Cancer"},{"key":"994_CR55","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2147\/OV.S56322","volume":"3","author":"S Bradley","year":"2014","unstructured":"Bradley, S., Jakes, A. D., Harrington, K., Pandha, H., Melcher, A. & Errington-Mais, F. Applications of coxsackievirus A21 in oncology. Oncol. Virother. 3, 47\u201355 (2014).","journal-title":"Oncol. Virother."},{"issue":"Suppl 2","key":"994_CR56","doi-asserted-by":"publisher","first-page":"P343","DOI":"10.1186\/2051-1426-3-S2-P343","volume":"3","author":"RH Andtbacka","year":"2015","unstructured":"Andtbacka, R. H., Curti, B. D., Hallmeyer, S., Feng, Z., Paustian, C., Bifulco, C. et al. Phase II CALM extension study: Coxsackievirus A21 delivered intratumorally to patients with advanced melanoma induces immune-cell infiltration in the tumor microenvironment. J. Immunother. Cancer 3(Suppl 2), P343 (2015).","journal-title":"J. Immunother. Cancer"},{"key":"994_CR57","doi-asserted-by":"publisher","first-page":"149","DOI":"10.3389\/fonc.2017.00149","volume":"7","author":"IR Eissa","year":"2017","unstructured":"Eissa, I. R., Naoe, Y., Bustos-Villalobos, I., Ichinose, T., Tanaka, M., Zhiwen, W. et al. Genomic signature of the natural oncolytic herpes simplex virus HF10 and its therapeutic role in preclinical and clinical trials. Front. Oncol. 7, 149 (2017).","journal-title":"Front. Oncol."},{"key":"994_CR58","doi-asserted-by":"crossref","unstructured":"Fein, S., Guttman, L., Marino, M.T. & Fong, Y. A first-in-human phase 1 ascending, multiple dose, safety and tolerance study of Vaxinia (CF33-hNIS), a novel chimeric oncolytic poxvirus, administered intratumorally or intravenously in adult patients with mixed advanced solid tumors (MAST) (American Association for Cancer Research Annual Meeting, Washington, DC, 2020).","DOI":"10.1158\/1538-7445.AM2020-CT243"},{"key":"994_CR59","unstructured":"ClinicalTrials.gov. Immunization strategy with intra-tumoral injections of Pexa-Vec with ipilimumab in metastatic\/advanced solid tumors. (ISI-JX). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02977156?intr=JX-594&draw=2&rank=17 (2019)."},{"key":"994_CR60","unstructured":"ClinicalTrials.gov. A pilot study of sequential ONCOS-102, an engineered oncolytic adenovirus expressing GM-CSF, and pembrolizumab in patients with advanced or unresectable melanoma progressing after programmed cell death protein 1 (PD1) blockade. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03003676?cond=Melanoma&intr=ONCOS102&rank=1 (2019)."},{"issue":"Suppl 1","key":"994_CR61","first-page":"236","volume":"7","author":"M Middleton","year":"2019","unstructured":"Middleton, M., Sacco, J., Merchan, J., Thomassen, A., Curti, B., VanderWalde, A. et al. Initial results of the phase 1 portion of an ongoing phase 1\/2 study of RP1 as a single agent and in combination with nivolumab in patients with solid tumors. J. Immunother. Cancer 7(Suppl 1), 236 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"994_CR62","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1093\/annonc\/mdx179","volume":"28","author":"T Shekarian","year":"2017","unstructured":"Shekarian, T., Valsesia-Wittmann, S., Brody, J., Michallet, M. C., Depil, S., Caux, C. et al. Pattern recognition receptors: immune targets to enhance cancer immunotherapy. Ann. Oncol. 28, 1756\u20131766 (2017).","journal-title":"Ann. Oncol."},{"key":"994_CR63","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.cell.2010.01.022","volume":"140","author":"O Takeuchi","year":"2010","unstructured":"Takeuchi, O. & Akira, S. Pattern recognition receptors and inflammation. Cell 140, 805\u2013820 (2010).","journal-title":"Cell"},{"key":"994_CR64","doi-asserted-by":"publisher","first-page":"211","DOI":"10.3390\/biomedicines2030211","volume":"2","author":"D Melisi","year":"2014","unstructured":"Melisi, D., Frizziero, M., Tamburrino, A., Zanotto, M., Carbone, C., Piro, G. et al. Toll-like receptor 9 agonists for cancer therapy. Biomedicines 2, 211\u2013228 (2014).","journal-title":"Biomedicines"},{"issue":"Suppl 8","key":"994_CR65","doi-asserted-by":"publisher","first-page":"viii736","DOI":"10.1093\/annonc\/mdy424.055","volume":"29","author":"GV Long","year":"2018","unstructured":"Long, G. V., Milhem, M., Amin, A., Hoimes, C. J., Medina, D., Conry, R. et al. Phase Ib\/II, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are nai\u0308ve to anti-PD-1\/L1 therapy. Ann. Oncol. 29(Suppl 8), viii736 (2018).","journal-title":"Ann. Oncol."},{"key":"994_CR66","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1158\/2159-8290.CD-18-0280","volume":"8","author":"A Ribas","year":"2018","unstructured":"Ribas, A., Medina, T., Kummar, S., Amin, A., Kalbasi, A., Drabick, J. J. et al. SD-101 in combination with pembrolizumab in advanced melanoma: results of a phase Ib, multicenter study. Cancer Disco. 8, 1250\u20131257 (2018).","journal-title":"Cancer Disco."},{"issue":"Suppl 1","key":"994_CR67","doi-asserted-by":"crossref","first-page":"B44","DOI":"10.1158\/2326-6074.TUMIMM16-B44","volume":"5","author":"J Barsoum","year":"2017","unstructured":"Barsoum, J., Renn, M., Schuberth, C., Jakobs, C., Schwickart, A., Schlee, M. et al. Selective stimulation of RIG-I with a novel synthetic RNA induces strong anti-tumor immunity in mouse tumor models. Cancer Immunol. Res. 5(Suppl 1), B44 (2017).","journal-title":"Cancer Immunol. Res."},{"key":"994_CR68","first-page":"283ra252","volume":"7","author":"J Fu","year":"2015","unstructured":"Fu, J., Kanne, D. B., Leong, M., Glickman, L. H., McWhirter, S. M., Lemmens, E. et al. STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade. Sci. Transl. Med. 7, 283ra252 (2015).","journal-title":"Sci. Transl. Med."},{"key":"994_CR69","unstructured":"ClinicalTrials.gov. Study of the safety and efficacy of MIW815 (ADU-S100) in patients with advanced\/metastatic solid tumors or lymphomas. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02675439 (2017)."},{"key":"994_CR70","unstructured":"ClinicalTrials.gov. Study of the safety and efficacy of MIW815 with PDR001 to patients with advanced\/metastatic solid tumors or lymphomas. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03172936?intr=ADU-S100&rank=2 (2019)."},{"key":"994_CR71","unstructured":"ClinicalTrials.gov. Study of MK-1454 alone or in combination with pembrolizumab in participants with advanced\/metastatic solid tumors or lymphomas (MK-1454-001). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03010176?intr=MK-1454&rank=1 (2019)."},{"issue":"Suppl 2","key":"994_CR72","first-page":"122","volume":"5","author":"DH Johnson","year":"2017","unstructured":"Johnson, D. H., Lecagoonporn, S., Beratchez, C., Haymaker, C., Bentebibel, S., Uemura, M. et al. Phase I\/II safety and efficacy study of image guided intratumoral CD40 agonistic monoclonal antibody APX005M in combination with systemic pembrolizumab in metastatic melanoma patients. J. Immunother. Cancer 5(Suppl 2), 122 (2017).","journal-title":"J. Immunother. Cancer"},{"issue":"Suppl 1","key":"994_CR73","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1200\/JCO.2018.36.5_suppl.188","volume":"36","author":"I Samoylenko","year":"2018","unstructured":"Samoylenko, I., Korotkova, O. V., Zabotina, T. & Demidov, L. V. Intralesional anti-PD1 treatment in patients with metastatic melanoma: the pilot study. J. Clin. Oncol. 36(Suppl 1), 188 (2018).","journal-title":"J. Clin. Oncol."},{"key":"994_CR74","unstructured":"ClinicalTrials.gov. A trial evaluating the safety & efficacy of intra-tumoral ipilimumab in combination with intra-venous nivolumab in patients with metastatic melanoma (NIVIPIT). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02857569?term=nivolumab&cond=melanoma&draw=5&rank=44 (2016)."},{"key":"994_CR75","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1158\/2326-6066.CIR-13-0206","volume":"2","author":"B Weide","year":"2014","unstructured":"Weide, B., Eigentler, T. K., Pflugfelder, A., Zelba, H., Martens, A., Pawelec, G. et al. Intralesional treatment of stage III metastatic melanoma patients with L19-IL2 results in sustained clinical and systemic immunologic responses. Cancer Immunol. Res. 2, 668\u2013678 (2014).","journal-title":"Cancer Immunol. Res."},{"key":"994_CR76","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.2217\/imt-2017-0096","volume":"9","author":"DA Canton","year":"2017","unstructured":"Canton, D. A., Shirley, S., Wright, J., Connolly, R., Burkart, C., Mukhopadhyay, A. et al. Melanoma treatment with intratumoral electroporation of tavokinogene telseplasmid (pIL-12, tavokinogene telseplasmid). Immunotherapy 9, 1309\u20131321 (2017).","journal-title":"Immunotherapy"},{"key":"994_CR77","unstructured":"Philogen S.p.A. Neoadjuvant L19IL2\/L19TNF- Pivotal Study (Pivotal). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02938299?term=NCT02938299&rank=1 (2016)."},{"key":"994_CR78","unstructured":"Algazi, A., Tsai, K.K., Bannavong, D., Shainsky, V., Talia, R., Browning, E., et al. Clinical immune monitoring and biomarker data of tavo monotherapy compared to tavo with pembrolizumab in metastatic melanoma supports the rationale for combination therapy. https:\/\/oncosec.com\/wp-content\/uploads\/2018\/06\/Algazi-SMR-10-19-17-FINAL.pdf (2017)."},{"key":"994_CR79","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.3389\/fimmu.2017.01829","volume":"8","author":"M Bedard","year":"2017","unstructured":"Bedard, M., Salio, M. & Cerundolo, V. Harnessing the power of invariant natural killer T cells in cancer immunotherapy. Front. Immunol. 8, 1829 (2017).","journal-title":"Front. Immunol."},{"key":"994_CR80","unstructured":"ClinicalTrials.gov. Study to evaluate safety & tolerability of AGI-134 in solid tumour. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03593226?intr=AGI-134&rank=1 (2019)."},{"key":"994_CR81","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-019-1059-8","volume":"19","author":"SM Shaw","year":"2019","unstructured":"Shaw, S. M., Middleton, J., Wigglesworth, K., Charlemagne, A., Schulz, O., Glossop, M. S. et al. AGI-134: a fully synthetic alpha-Gal glycolipid that converts tumors into in situ autologous vaccines, induces anti-tumor immunity and is synergistic with an anti-PD-1 antibody in mouse melanoma models. Cancer Cell Int. 19, 346 (2019).","journal-title":"Cancer Cell Int."},{"key":"994_CR82","unstructured":"ClinicalTrials.gov. pDNA intralesional cancer vaccine for cutaneous melanoma. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03655756 (2018)."},{"key":"994_CR83","doi-asserted-by":"crossref","unstructured":"Markowitz, J., Brohl, A., Sarnaik, A.A., Eroglu, Z., De Aquino, D.B., Khushalani, N., et al. Trial in progress: IFx-Hu2.0 (plasmid DNA coding for Emm55 streptococcal antigen in a cationic polymer) phase I first in human study for unresectable stage III or stage IV cutaneous melanoma. (American Association for Cancer Research Annual Meeting, Washington, DC, 2020).","DOI":"10.1158\/1538-7445.AM2020-CT241"},{"key":"994_CR84","doi-asserted-by":"crossref","unstructured":"Jimeno, A., Gupta, S., Sullivan, R., Do, J. T., Akerley, W. L., Wang, D., et al. A phase 1\/2, open-label, multicenter, dose escalation and efficacy study of mRNA-2416, a lipid nanoparticle encapsulated mRNA encoding human OX40L, for intratumoral injection alone or in combination with durvalumab for patients with advanced malignancies. (American Association for Cancer Research Annual Meeting, Washington, DC, 2020).","DOI":"10.1158\/1538-7445.AM2020-CT032"},{"key":"994_CR85","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1007\/s00262-016-1860-3","volume":"65","author":"C Hoeller","year":"2016","unstructured":"Hoeller, C., Michielin, O., Ascierto, P. A., Szabo, Z. & Blank, C. U. Systematic review of the use of granulocyte\u2013macrophage colony-stimulating factor in patients with advanced melanoma. Cancer Immunol. Immunother. 65, 1015\u20131034 (2016).","journal-title":"Cancer Immunol. Immunother."},{"key":"994_CR86","unstructured":"Andtbacka, R.H., Gonzalez, R., Wloch, M.K., Strause, L., Stardal, K., Chu, A., et al. A phase 3 clinical trial to evaluate the safety and efficacy of treatment with 2 mg intralesional Allovectin-7 compared to dacarbazine or temozolomide in subjects with recurrent metastatic melanoma. (10th International Meeting of the Society for Melanoma Research, Philadelphia, 2013)."},{"key":"994_CR87","unstructured":"Sciencemag. A promising new cancer drug has hit a major setback, raising questions about whether the field is moving too fast. http:\/\/www.sciencemag.org\/news\/2018\/05\/promising-new-cancer-drug-has-hit-major-setback-raising-questions-about-whether-field (2018)."},{"key":"994_CR88","doi-asserted-by":"publisher","first-page":"e731","DOI":"10.1016\/S1470-2045(17)30607-1","volume":"18","author":"NL Syn","year":"2017","unstructured":"Syn, N. L., Teng, M. W. L., Mok, T. S. K. & Soo, R. A. De-novo and acquired resistance to immune checkpoint targeting. Lancet Oncol. 18, e731\u2013e741 (2017).","journal-title":"Lancet Oncol."},{"key":"994_CR89","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature21349","volume":"541","author":"DS Chen","year":"2017","unstructured":"Chen, D. S. & Mellman, I. Elements of cancer immunity and the cancer\u2013immune set point. Nature 541, 321 (2017).","journal-title":"Nature"},{"key":"994_CR90","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1111\/joim.12470","volume":"279","author":"S Muenst","year":"2016","unstructured":"Muenst, S., Laubli, H., Soysal, S. D., Zippelius, A., Tzankov, A. & Hoeller, S. The immune system and cancer evasion strategies: therapeutic concepts. J. Intern Med. 279, 541\u2013562 (2016).","journal-title":"J. Intern Med."},{"key":"994_CR91","doi-asserted-by":"publisher","first-page":"12452","DOI":"10.18632\/oncotarget.23746","volume":"9","author":"R Marconcini","year":"2018","unstructured":"Marconcini, R., Spagnolo, F., Stucci, L. S., Ribero, S., Marra, E., Rosa, F. et al. Current status and perspectives in immunotherapy for metastatic melanoma. Oncotarget 9, 12452\u201312470 (2018).","journal-title":"Oncotarget"},{"key":"994_CR92","doi-asserted-by":"crossref","unstructured":"Long, G. V., Dummer, R., Ribas, A., Puzanov, I., VanderWalde, A., Andtbacka, R. H., et al. Efficacy analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec and pembrolizumab for unresectable stage IIIB\u2013IV melanoma. J. Clin. Oncol. 15(Suppl), abstract 9568 (2016).","DOI":"10.1200\/JCO.2016.34.15_suppl.9568"},{"key":"994_CR93","first-page":"133","volume":"32","author":"GV Long","year":"2019","unstructured":"Long, G. V., Dummer, R., Andtbacka, R., Johnson, D., Michielin, O., Martin-Algarra, S. et al. Follow-up analysis of MASTERKEY-265 phase 1b (ph1b) study of talimogene laherparepvec (T-VEC) in combination (combo) with pembrolizumab (pembro) in patients (pts) with unresectable stage IIIB\u2013IVM1c melanoma (MEL). Pigment Cell Melanoma Res. 32, 133\u2013134 (2019).","journal-title":"Pigment Cell Melanoma Res."},{"key":"994_CR94","unstructured":"ClinicalTrials.gov. Pembrolizumab with or without talimogene laherparepvec or talimogene laherparepvec placebo in unresected melanoma (KEYNOTE-034). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02263508?cond=Melanoma&intr=talimogene+laherparepvec&phase=2&rank=3 (2018)."},{"issue":"Suppl 3","key":"994_CR95","first-page":"14","volume":"5","author":"A Algazi","year":"2017","unstructured":"Algazi, A., Tsai, K. K., Rosenblum, M. D., Andtbacka, R. H., Ballesteros-Merino, C., Jensen, S. et al. Clinical and biomarker analyses of a phase II study of intratumoral tavokinogene telseplasmid (Pil-12) plus pembrolizumab in stage III\/IV melanoma patients predicted to not respond to anti-PD-1. J. Immunother. Cancer 5(Suppl 3), 14 (2017).","journal-title":"J. Immunother. Cancer"},{"key":"994_CR96","unstructured":"ClinicalTrials.gov. Efficacy, safety, and tolerability of V937 administered intravenously or intratumorally with pembrolizumab (MK-3475) versus pembrolizumab alone in participants with advanced\/metastatic melanoma (V937-011). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04152863 (2019)."},{"key":"994_CR97","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1200\/JCO.2016.67.1529","volume":"34","author":"I Puzanov","year":"2016","unstructured":"Puzanov, I., Milhem, M. M., Minor, D., Hamid, O., Li, A., Chen, L. et al. Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma. J. Clin. Oncol. 34, 2619\u20132626 (2016).","journal-title":"J. Clin. Oncol."},{"issue":"Suppl 1","key":"994_CR98","doi-asserted-by":"publisher","first-page":"9509","DOI":"10.1200\/JCO.2017.35.15_suppl.9509","volume":"35","author":"J Chesney","year":"2017","unstructured":"Chesney, J., Puzanov, I., Ross, M., Collichio, F., Milhem, M., Chen, L. et al. Primary results from a randomized (1:1), open-label phase II study of talimogene laherparepvec (T) and ipilimumab (I) vs I alone in unresected stage IIIB\u2013IV melanoma. J. Clin. Oncol. 35(Suppl 1), 9509 (2017).","journal-title":"J. Clin. Oncol."},{"issue":"Suppl 5","key":"994_CR99","doi-asserted-by":"publisher","first-page":"v906","DOI":"10.1093\/annonc\/mdz394.067","volume":"30","author":"JA Chesney","year":"2019","unstructured":"Chesney, J. A., Puzanov, I., Collichio, F., Singh, P., Milhem, M., Glaspy, J. et al. Talimogene laherparepvec (T-VEC) in combination (combo) with ipilimumab (ipi) versus ipi alone for advanced melanoma: 3-year landmark analysis of a randomized, open-label, phase II trial. Ann. Oncol. 30(Suppl 5), v906\u2013v907 (2019).","journal-title":"Ann. Oncol."},{"issue":"Suppl 1","key":"994_CR100","doi-asserted-by":"publisher","first-page":"9510","DOI":"10.1200\/JCO.2017.35.15_suppl.9510","volume":"35","author":"RH Andtbacka","year":"2017","unstructured":"Andtbacka, R. H., Ross, M., Agarwala, S. S., Taylor, M., Vetto, J., Neves, R. I. et al. Final results of a phase II multicenter trial of HF10, a replication-competent HSV-1 oncolytic virus, and ipilimumab combination treatment in patients with stage IIIB-IV unresectable or metastatic melanoma. J. Clin. Oncol. 35(Suppl 1), 9510 (2017).","journal-title":"J. Clin. Oncol."},{"issue":"Suppl 5","key":"994_CR101","doi-asserted-by":"publisher","first-page":"v557","DOI":"10.1093\/annonc\/mdz255.053","volume":"30","author":"K Yokota","year":"2019","unstructured":"Yokota, K., Isei, T., Uhara, H., Fujisawa, Y., Takenouchi, T., Kiyohara, Y. et al. Final results from phase II of combination with canerpaturev (formerly HF10), an oncolytic viral immunotherapy, and ipilimumab in unresectable or metastatic melanoma in second-or later line treatment. Ann. Oncol. 30(Suppl 5), v557 (2019).","journal-title":"Ann. Oncol."},{"key":"994_CR102","unstructured":"ClinicalTrials.gov. A study of IMO-2125 in combination with ipilimumab versus ipilimumab alone in subjects with anti-PD-1 refractory melanoma (ILLUMINATE-301). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03445533?cond=Melanoma&intr=Ipilimumab&phase=2&rank=1 (2018)."},{"issue":"Suppl 1","key":"994_CR103","doi-asserted-by":"publisher","first-page":"TPS9603","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS9603","volume":"36","author":"S Hu-Lieskovan","year":"2018","unstructured":"Hu-Lieskovan, S., Moon, J., Campos, D., Grossmann, K. F., Sosman, J. A., Ryan, C. W. et al. Reversing resistance to PD-1 blockade by combination of talimogene laherparepvec (T-VEC) with pembrolizumab (pembro) in advanced melanoma patients following progression on a prior PD-1 inhibitor: SWOG S1607 (NCT#02965716). J. Clin. Oncol. 36(Suppl 1), TPS9603 (2018).","journal-title":"J. Clin. Oncol."},{"key":"994_CR104","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","volume":"378","author":"AMM Eggermont","year":"2018","unstructured":"Eggermont, A. M. M., Blank, C. U., Mandala, M., Long, G. V., Atkinson, V., Dalle, S. et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N. Engl. J. Med. 378, 1789\u20131801 (2018).","journal-title":"N. Engl. J. Med."},{"key":"994_CR105","first-page":"1103","volume":"10","author":"A Alqathama","year":"2020","unstructured":"Alqathama, A. BRAF in malignant melanoma progression and metastasis: potentials and challenges. Am. J. Cancer Res. 10, 1103\u20131114 (2020).","journal-title":"Am. J. Cancer Res."},{"key":"994_CR106","doi-asserted-by":"publisher","first-page":"eaau0417","DOI":"10.1126\/scitranslmed.aau0417","volume":"10","author":"PK Bommareddy","year":"2018","unstructured":"Bommareddy, P. K., Aspromonte, S., Zloza, A., Rabkin, S. D. & Kaufman, H. L. MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation. Sci. Transl. Med. 10, eaau0417 (2018).","journal-title":"Sci. Transl. Med."},{"key":"994_CR107","unstructured":"ClinicalTrials.gov. Combining talimogene laherparepvec with BRAF and MEK inhibitors in BRAF mutated advanced melanoma. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03088176 (2017)."},{"key":"994_CR108","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1684\/ejd.2018.3447","volume":"28","author":"R Gutzmer","year":"2018","unstructured":"Gutzmer, R., Harrington, K., Hoeller, C., Lebbe, C., Malvehy, J., Ohrling, K. et al. Practical clinical guide for the use of talimogene laherparepvec monotherapy in patients with unresectable melanoma in Europe. Eur. J. Dermatol. 28, 736\u2013749 (2018).","journal-title":"Eur. J. Dermatol."},{"key":"994_CR109","doi-asserted-by":"publisher","first-page":"3867","DOI":"10.2147\/OTT.S133699","volume":"10","author":"KJ Harrington","year":"2017","unstructured":"Harrington, K. J., Michielin, O., Malvehy, J., Pezzani Gruter, I., Grove, L., Frauchiger, A. L. et al. A practical guide to the handling and administration of talimogene laherparepvec in Europe. Onco Targets Ther. 10, 3867\u20133880 (2017).","journal-title":"Onco Targets Ther."},{"key":"994_CR110","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.2217\/imt-2017-0096","volume":"9","author":"DA Canton","year":"2017","unstructured":"Canton, D. A., Shirley, S., Wright, J., Connolly, R., Burkart, C., Mukhopadhyay, A. et al. Melanoma treatment with intratumoral electroporation of tavokinogene telseplasmid (pIL-12, tavokinogene telseplasmid). Immunotherapy 9, 1309\u20131321 (2017).","journal-title":"Immunotherapy"},{"key":"994_CR111","first-page":"76","volume":"21","author":"V Seery","year":"2017","unstructured":"Seery, V. Intralesional therapy: consensus statements for best practices in administration from the melanoma nursing initiative. Clin. J. Oncol. Nurs. 21, 76\u201386 (2017).","journal-title":"Clin. J. Oncol. Nurs."},{"issue":"Suppl 6","key":"994_CR112","doi-asserted-by":"publisher","first-page":"vi393","DOI":"10.1093\/annonc\/mdw379.41","volume":"27","author":"RH Andtbacka","year":"2016","unstructured":"Andtbacka, R. H., Ross, M., Agarwala, S. S., Taylor, M., Vetto, J., Neves, R. I. et al. Tumour response from phase II study of combination treatment with intratumoral HF10, a replication competent HSV-1 oncolytic virus, and ipilimumab in patients with stage IIIB, IIIC, or IV unresectable or metastatic melanoma. Ann. Oncol. 27(Suppl 6), vi393 (2016).","journal-title":"Ann. Oncol."},{"key":"994_CR113","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1200\/JCO.2015.64.0391","volume":"34","author":"FS Hodi","year":"2016","unstructured":"Hodi, F. S., Hwu, W. J., Kefford, R., Weber, J. S., Daud, A., Hamid, O. et al. Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. J. Clin. Oncol. 34, 1510\u20131517 (2016).","journal-title":"J. Clin. Oncol."},{"key":"994_CR114","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","volume":"18","author":"L Seymour","year":"2017","unstructured":"Seymour, L., Bogaerts, J., Perrone, A., Ford, R., Schwartz, L. H., Mandrekar, S. et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 18, e143\u2013e152 (2017).","journal-title":"Lancet Oncol."},{"key":"994_CR115","doi-asserted-by":"publisher","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","volume":"15","author":"JD Wolchok","year":"2009","unstructured":"Wolchok, J. D., Hoos, A., O\u2019Day, S., Weber, J. S., Hamid, O., Lebbe, C. et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. 15, 7412\u20137420 (2009).","journal-title":"Clin. Cancer Res."},{"key":"994_CR116","doi-asserted-by":"publisher","first-page":"3936","DOI":"10.1158\/1078-0432.CCR-13-0895","volume":"19","author":"M Nishino","year":"2013","unstructured":"Nishino, M., Giobbie-Hurder, A., Gargano, M., Suda, M., Ramaiya, N. H. & Hodi, F. S. Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clin. Cancer Res. 19, 3936\u20133943 (2013).","journal-title":"Clin. Cancer Res."},{"issue":"Suppl 1","key":"994_CR117","doi-asserted-by":"publisher","first-page":"9508","DOI":"10.1200\/JCO.2018.36.15_suppl.9508","volume":"36","author":"RHI Andtbacka","year":"2018","unstructured":"Andtbacka, R. H. I., Dummer, R., Gyorki, D. E., Berger, A. C., Conry, R. M., Demidov, L. V. et al. Interim analysis of a randomized, open-label phase 2 study of talimogene laherparepvec (T-VEC) neoadjuvant treatment (neotx) plus surgery (surgx) vs surgx for resectable stage IIIB-IVM1a melanoma (MEL). J. Clin. Oncol. 36(Suppl 1), 9508 (2018).","journal-title":"J. Clin. Oncol."},{"key":"994_CR118","doi-asserted-by":"publisher","first-page":"31","DOI":"10.4049\/jimmunol.1601145","volume":"198","author":"MA Aznar","year":"2017","unstructured":"Aznar, M. A., Tinari, N., Rullan, A. J., Sanchez-Paulete, A. R., Rodriguez-Ruiz, M. E. & Melero, I. Intratumoral delivery of immunotherapy-act locally, think globally. J. Immunol. 198, 31\u201339 (2017).","journal-title":"J. Immunol."},{"key":"994_CR119","doi-asserted-by":"publisher","first-page":"7081","DOI":"10.2147\/OTT.S115245","volume":"9","author":"KJ Harrington","year":"2016","unstructured":"Harrington, K. J., Andtbacka, R. H., Collichio, F., Downey, G., Chen, L., Szabo, Z. et al. Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB\/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trial. Onco Targets Ther. 9, 7081\u20137093 (2016).","journal-title":"Onco Targets Ther."},{"issue":"Suppl 1","key":"994_CR120","doi-asserted-by":"publisher","first-page":"3014","DOI":"10.1200\/JCO.2017.35.15_suppl.3014","volume":"35","author":"B Curti","year":"2017","unstructured":"Curti, B., Richards, J., Hallmeyer, S., Faries, M. B., Andtbacka, R. H. I., Daniels, G. et al. Activity of a novel immunotherapy combination of intralesional Coxsackievirus A21 and systemic ipilimumab in advanced melanoma patients previously treated with anti-PD1 blockade therapy. J. Clin. Oncol. 35(Suppl 1), 3014 (2017).","journal-title":"J. Clin. Oncol."},{"issue":"Suppl 8","key":"994_CR121","doi-asserted-by":"publisher","first-page":"viii452","DOI":"10.1093\/annonc\/mdy289.023","volume":"29","author":"T Isei","year":"2018","unstructured":"Isei, T., Yokota, K., Uhara, H., Fujisawa, Y., Takenouchi, T., Kiyohara, Y. et al. Topline results from phase II of combination treatment with canerpaturev (HF10), an oncolytic viral immunotherapy, and ipilimumab in patients with unresectable or metastatic melanoma after anti-PD-1 therapy. Ann. Oncol. 29(Suppl 8), viii452\u2013viii453 (2018).","journal-title":"Ann. Oncol."},{"key":"994_CR122","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","volume":"39","author":"DS Chen","year":"2013","unstructured":"Chen, D. S. & Mellman, I. Oncology meets immunology: the cancer-immunity cycle. Immunity 39, 1\u201310 (2013).","journal-title":"Immunity"},{"key":"994_CR123","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1002\/hed.24522","volume":"38","author":"RH Andtbacka","year":"2016","unstructured":"Andtbacka, R. H., Agarwala, S. S., Ollila, D. W., Hallmeyer, S., Milhem, M., Amatruda, T. et al. Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB\/IIIC\/IV melanoma. Head Neck 38, 1752\u20131758 (2016).","journal-title":"Head Neck"},{"key":"994_CR124","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s40425-016-0158-5","volume":"4","author":"H Rehman","year":"2016","unstructured":"Rehman, H., Silk, A. W., Kane, M. P. & Kaufman, H. L. Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy. J. Immunother. Cancer 4, 53 (2016).","journal-title":"J. Immunother. Cancer"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-020-0994-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-020-0994-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-020-0994-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T20:30:03Z","timestamp":1723321803000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-020-0994-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,27]]},"references-count":124,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,9,15]]}},"alternative-id":["994"],"URL":"https:\/\/doi.org\/10.1038\/s41416-020-0994-4","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,27]]},"assertion":[{"value":"17 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This review article does not report new data from any studies with human participants or animals performed by any of the authors.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Not applicable (no datasets were generated or analysed during article).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"M.R.M. has acted as an advisor for Alkermes, Amgen, Astellas (was OSI), Bioline, Boehringer Ingelheim, Bristol-Myers Squibb, Codiak, CytomX, Eisai, GSK, Kineta, Merck, Novartis, Roche, Silicon Therapeutics and Valo Therapeutics; has received grants from AstraZeneca, GSK and Roche; and has received other types of support from Immunocore, Pfizer, Regeneron, Replimune, TC Biopharma, and Vertex. C.H. has acted as a speaker or advisor for Amgen, Bristol-Myers Squibb, Incyte, Merck Sharp & Dohme, Novartis, Pierre Fabre and Roche. O.M. has received honoraria for advisory roles from Amgen, Bristol-Myers Squibb, Novartis and Roche, and research funding from MSD. Caroline Robert has participated in advisory boards for Amgen, Biothera, Bristol-Myers Squibb, Merck Sharp & Dohme, Novartis and Roche. C.C. has received honoraria for advisory roles from Amgen, AstraZeneca, Bristol-Myers Squibb and Roche. K.\u00d6. is an employee of Amgen (Europe) GmbH and is a stockholder in Amgen. A.H. has received grants and honoraria from Amgen, Bristol-Myers Squibb, Merck Serono, Merck Sharp & Dohme, Philogen, Pierre Fabre, Provectus, Regeneron and Roche, and has received honoraria from OncoSec.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Medical writing support was funded by Amgen (Europe) GmbH.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding information"}}]}}